John Leonard, MD, discusses the inefficacy of early treatment and treatment options for patients with follicular lymphoma. Leonard says the relapse rate for patients with follicular lymphoma is around 80%.
John Leonard, MD, medical oncologist, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses the inefficacy of early treatment and treatment options for patients with follicular lymphoma. Leonard says the relapse rate for patients with follicular lymphoma is around 80%, though most patients with the malignancy will not pass away from their disease.
Leonard adds that data from recent studies also shows that early treatment of follicular lymphoma does not improve long-term outcomes. After relapse, Leonard says patients should be asking their doctors if they should be doing anything post-relapse and, if so, what the options are. Leonard says one thing doctors should be looking out for is symptomatic progression in patients with follicular lymphoma, at which point treatment should be considered.
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
March 22nd 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Read More